Moreover, Couto et al. confirmed that the use of hybrid erlotinib with boron clusters as potential EGFR inhibitors were most effective in U-87 MG and HT-29 cancer cells compared to unmodified erlotinib treatment. The gene discussed is EGFR; the disease is cancer.